The stock of Geron Corp. (GERN) has seen a -0.90% decrease in the past week, with a 59.81% gain in the past month, and a 42.86% flourish in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 10.62% for GERN. The simple moving average for the last 20 days is 26.09% for GERN stock, with a simple moving average of 39.79% for the last 200 days.
Is It Worth Investing in Geron Corp. (NASDAQ: GERN) Right Now?
GERN has 36-month beta value of 0.61. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GERN is 447.58M, and currently, short sellers hold a 11.38% ratio of that float. The average trading volume of GERN on April 01, 2024 was 11.24M shares.
GERN) stock’s latest price update
Geron Corp. (NASDAQ: GERN)’s stock price has plunge by -0.30relation to previous closing price of 3.31. Nevertheless, the company has seen a -0.90% plunge in its stock price over the last five trading sessions. MarketBeat reported 2024-03-20 that Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.
Analysts’ Opinion of GERN
Many brokerage firms have already submitted their reports for GERN stocks, with Needham repeating the rating for GERN by listing it as a “Buy.” The predicted price for GERN in the upcoming period, according to Needham is $5 based on the research report published on March 15, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see GERN reach a price target of $4. The rating they have provided for GERN stocks is “Buy” according to the report published on September 12th, 2023.
Goldman gave a rating of “Neutral” to GERN, setting the target price at $3 in the report published on March 28th of the previous year.
GERN Trading at 46.68% from the 50-Day Moving Average
After a stumble in the market that brought GERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.65% of loss for the given period.
Volatility was left at 10.62%, however, over the last 30 days, the volatility rate increased by 3.65%, as shares surge +69.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +67.51% upper at present.
During the last 5 trading sessions, GERN fell by -0.90%, which changed the moving average for the period of 200-days by -8.33% in comparison to the 20-day moving average, which settled at $2.68. In addition, Geron Corp. saw 56.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GERN starting from O’Farrell Elizabeth G., who purchase 6,607 shares at the price of $2.28 back on Aug 24 ’23. After this action, O’Farrell Elizabeth G. now owns 7,407 shares of Geron Corp., valued at $15,064 using the latest closing price.
O’Farrell Elizabeth G., the Director of Geron Corp., purchase 6,579 shares at $2.28 during a trade that took place back on Aug 24 ’23, which means that O’Farrell Elizabeth G. is holding 26,220 shares at $15,000 based on the most recent closing price.
Stock Fundamentals for GERN
Current profitability levels for the company are sitting at:
- -818.33 for the present operating margin
- -126.4 for the gross margin
The net margin for Geron Corp. stands at -776.71. The total capital return value is set at -0.68. Equity return is now at value -112.29, with -62.99 for asset returns.
Based on Geron Corp. (GERN), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -2.02. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -46.4.
Currently, EBITDA for the company is -192.91 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 7665.64. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.16.
Conclusion
To put it simply, Geron Corp. (GERN) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
